Dr Tom Gajewski (Chicago) and Dr Roberta Zappasodi (MSKCC) in plenary biomarker session
Today, the 2017 annual meeting of the American Association for Cancer Research (AACR) kicked into gear with multiple sessions from early morning until late into the evening (Twitter #AACR17)
Above all else the meeting showcases the value of scientific research, and how improving our knowledge of cancer biology is the foundation upon which new drugs and therapies are developed.
If you know or want to know why cancer can be cured in mice but not in humans, then the AACR annual meeting is the place for you.
In today’s post we’re again providing some end of the day topline commentary on the sessions we attended and the data we heard. We also did several expert interviews that we’ll be writing up in forthcoming weeks.
Subscribers can login to read more or you can purchase access below…
Waiting in line for the White House Tour
The 2017 annual meeting of the American Association for Cancer Research in Washington DC (Twitter #AACR17) officially starts tomorrow, but today was a day full of educational sessions and workshops.
After a day of rain yesterday, it was good to have a dry day for the start of the world’s leading cancer science meeting.
In this post we offer some top-line commentary on those educational sessions we attended; the choice reflects personal interests or current fetishes.
By definition, there is far more excellent research at AACR than we can possibly cover on the blog; so we encourage you to check out the AACR webcasts if you have a specific interest or want to check out a particular session.
We’d also like to congratulate AACR for moving with the times and allowing personal photography and the sharing of content on social media, except where a slide or presentation says “Do Not Post.”
The few slides that I saw today that had “Do Not Post” showed unpublished data. Our longstanding unwritten policy has been not to tweet or share on social media data that clearly states it is unpublished, so this was not an unreasonable request and one we heartily concur with in principle.
Subscribers can login to read more or you can purchase access below…
Following the recent approval of Clovis’s rucaparib (Rubraca) by FDA under priority review as monotherapy for the treatment of women with certain types of advanced ovarian cancer, then impressive SOLO-2 maintenance data after initial chemotherapy at SGO earlier this month, PARP inhibitors continue to be in the news.
There’s always more though!
This afternoon saw the approval of Tesaro’s PARP inhibitor niraparib (Zejula) by the US Food and Drug Administration (FDA) for maintenance treatment of women with ovarian cancer who are in a complete or partial response to platinum-based chemotherapy (Link to label).
Subscribers can login to read more or you can purchase access via the blue box below:
We’re continuing our coverage of highlights from the inaugural ASCO-SITC Clinical Immuno-Oncology Symposium with a look at a novel way to potentially improve the efficacy of checkpoint inhibitors.
It’s not something we’ve previously written about, nor is it included in the recent Chen & Mellman Nature paper that discusses “factors that influence the cancer-immune set point.”
So there’s a good chance it may not be on your radar either.
Given the commercial stakes at play in improving checkpoint efficacy, combination strategies that could have an impact are worth thinking about when it comes to designing clinical trials.
Subscribers can login to read more or you can purchase access by clicking on the blue box below.
Much of the focus in multiple myeloma over the last decade has focused on two key drug classes – proteasome inhibitors and IMiDs – with some recent approvals for monoclonal antibodies targeting key proteins on the surface of malignant myeloma cells such as CD38.
#ASH16 in San Diego
Combinations of these core therapies have lead to a noticeable improvement in outcomes for people living with the disease – from 3-4 years over a decade ago to now approaching 10 years post diagnosis.
If we want to continuously beat the status quo and improve on the chronicity, however, it is likely that several things will need to happen:
- Better understand mechanisms of resistance that induce relapse
- Develop predictive biomarkers of response
- Identify novel therapeutic targets
Here. we focus on the latest preclinical findings that were recently presented at the American Society of Hematology (ASH) in San Diego and explore where the future might be headed in this disease.
To learn more about these novel targets in early development, subscribers can log-in below or you can sign up via the blue box…
As we move from monotherapies to combinations in the immuno-oncology space, we start to see some intriguing ideas being explored from additional checkpoints to vaccines to neoantigens to immune agonists to oncolytic viruses. There are numerous ways to evaluate how to boost or jumpstart more immune cells upfront in the hope of seeing better efficacy.
One way to do this is to better understand the tumour microenvironment.
Wall of people at ASH16 in San Diego
If we know what’s wrong under the hood, we might be better able to make the immune system get going… more gas, faulty starter motor, dead battery, loose wire, broken fan belt? All these things and more might be a problem so you can see that diagnosing the issue up from from basic and translational work might be instructive for clinical trials.
If you don’t know what problem you’re trying to fix or repair then you might as well be throwing mud at the wall. Just as we don’t expect a car mechanic to suggest changing the battery or starter-motor without first diagnosing the issue, so understanding the tumour microenvironment in each different cancer or disease might also be a helpful strategy.
At the recent American Society of Hematology annual meeting (#ASH16), there was a fascinating sceintifc workshop that focused on this very concept – what’s going on under the hood and how do we go about fixing it?
Here we explore these ideas via an interview with a thought leader and specialist in the field. What he had to say was very interesting and candid indeed.
To learn more about these insights, subscribers can log-in or you can sign up via the blue box below…
At the recent 2016 San Antonio Breast Cancer Symposium (SABCS16), Cascadian Therapeutics (NASDAQ: CASC) presented a poster (Abstract #P4–21–01) on:
“Efficacy Results of a Phase 1b Study of Tucatinib (ONT–380), an Oral HER2-Specific Inhibitor, in Combination With Capecitabine and Trastuzumab in HER2+ Metastatic Breast Cancer, Including Patients with Brain Metastases.”
Tucatinib is an oral tyrosine kinase inhibitor that is highly selective for HER2.
Cascadian’s tucatinib poster at #SABCS16
We’ve seen several new treatments approved for HER2 positive breast cancers in recent years including four targeted treatments: trastuzumab, pertuzumab, lapatinib and T-DM1.
Other companies such as Puma Biotech (NASDAQ: PBYI) also have oral TKIs in development. Puma’s drug, neratinib has, however been shown to have a high incidence of grade 3+ diarrhea, raising questions about its tolerance.
At SABCS16 (Abstract P02–11–03), the company presented the interim analysis of an open-label, multicenter phase 2 trial, which explored their compound:
“Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC).”
There has been a lot of interest and controversy in this space, so it’s time to take a look at the latest events in HER2+ breast cancer and consider the ramifications since there are a number of new developments that are well worth following, including neratinib (Puma Biotech) and pertuzumab (Genentech).
Subscribers can login to read more or you can gain access via the blue box below…
Dr Max Wicha is the 2016 recipient of the AACR Distinguished Lectureship in Breast Cancer Research. At the 2016 San Antonio Breast Cancer Symposium (SABCS16) he gave his award lecture, “Targeting Breast Cancer Stem Cells: Challenges and Opportunities.”
SABC16 Dr Max Wicha Award Lecture
As the AACR press release notes, “This lectureship recognizes an outstanding scientist whose work has inspired or has the potential to inspire new perspectives on the etiology, diagnosis, treatment or prevention of breast cancer.”
Dr Wicha is a pioneer in the field of cancer stem cells, and is Director Emeritus of the University of Michigan Comprenhensive Cancer Center and a co-founder of OncoMed Pharmaceuticals (NASDAQ: OMED).
Targeting cancer stem cells is an area I expect we will hear a lot more about, particularly in breast cancer. Dr Wicha kindly spoke to BSB after his award lecture, which was one of my highlights of SABCS16.
In case you missed it, do check out the post from the 2016 EORTC-NCI-AACR Molecular Targets Symposium in Munich that featured Dr Mina Bisell (Berkeley), who was a previous recipient of the AACR Distinguished Lectureship in Breast Cancer Research award in 2012 (Link.)
This is the fifth in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium.
Subscribers can login to read more or you can gain access via the blue box below.
At the 2016 San Antonio Breast Cancer Symposium (SABCS16), I had the great pleasure to talk with a leading inflammatory breast cancer expert and translational researcher, Naoto T. Ueno MD PhD.
Dr Naoto Ueno at SABCS16
Dr Ueno is Executive Director of the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic at the University of Texas MD Anderson Cancer Center.
He’s active on Twitter where, as @teamoncology, he shares information on the latest developments in breast cancer, often writing in Japanese for his followers.
A cancer survivor himself, he also brings an empathy to patient care through his own treatment experience.
Anyone who follows him on Twitter, will also know he is a “foodie.” Prior to our chat, I joked he should write the definitive guide to San Antonio restaurants for attendees… he definitely ate better than I did at the meeting!
MD Anderson also has an IBC conference coming up next month for those interested in the area:
What caught my attention at SABCS16 were posters from MD Anderson researchers that offered insight into the challenges and opportunities in targeting this rare form of breast cancer, something we don’t hear a lot about.
Subscribers can login to read the interview Dr Ueno kindly gave BSB or you can gain access via the blue button below… this is the fourth in our series of expert interviews from San Antonio.
If you have a keen interest in IBC, do follow @teamoncology – if you don’t already!
We’re continuing our series of posts from the 2016 San Antonio Breast Cancer Symposium (SABCS) with an expert interview on how circulating tumor DNA could change breast cancer treatment.
There has been a noticeable increase in attention and focus on the application of liquid tests – especially from blood – over the last five years, culminating in a spinoff company called Grail from the deep sequencing giant, Illumina, announcing a massive funding round earlier this month.
At the time of the BSB expert interview in San Antonio, we had no idea that the Grail news was going to hit just a couple of weeks later!
While much of the media attention surrounding Grail has focused on the early detection of cancer in apparently healthy individuals, there’s actually a much more useful application where it could be more immediately applied to great effect.
Circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) has the potential to revolutionise and improve monitoring over time for people with cancer who are receiving therapy.
This is the third in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium (#SABCS16).
Subscribers can login to learn more about this exciting field or you can gain access via the blue button below.